Status:

TERMINATED

A Study of SC-007 in Subjects With Advanced Cancer

Lead Sponsor:

AbbVie

Conditions:

Colorectal Cancer (CRC)

Gastric Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen find...

Eligibility Criteria

Inclusion

  • Histologically or cytologically confirmed advanced metastatic or unresectable advanced colorectal cancer (CRC) or gastric cancer that is relapsed, refractory, or progressive after:
  • CRC: at least 2 prior systemic regimens in the metastatic setting, and as appropriate in patients whose tumors are microsatellite instability-high (MSI-H), pembrolizumab as well.
  • Gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 (HER2) targeted agent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hematologic, hepatic, and renal function.

Exclusion

  • Any significant medical condition that, in the opinion of the investigator or sponsor, may place the participant at undue risk from the study.
  • Has electrocardiogram (ECG) abnormalities that make QT interval corrected (QTc) evaluation difficult.
  • Prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.

Key Trial Info

Start Date :

September 13 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 2 2018

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT03253185

Start Date

September 13 2017

End Date

April 2 2018

Last Update

April 27 2018

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

University of California, Los Angeles

Los Angeles, California, United States, 90095

2

Mayo Clinic

Rochester, Minnesota, United States, 55905-0001

3

Washington University-School of Medicine

St Louis, Missouri, United States, 63110

4

Gabrail Cancer Center Research

Canton, Ohio, United States, 44718